Mexiprim, 125 mg 60 pcs.

Mexiprim belongs to the heteroaromatic antioxidants.

It has a wide range of pharmacological activity: increases the body’s resistance to stress, exhibits anxiolytic effect, not accompanied by myorelaxant effect; has nootropic properties, prevents and reduces learning and memory disorders that occur with aging and exposure to various pathogenic factors; has anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases attention concentration and performance; weakens the toxic effects of alcohol.

The drug improves brain tissue metabolism and blood supply, improves microcirculation and blood rheology, reduces platelet aggregation.

Stabilizes membrane structures of blood cells (erythrocytes and platelets). It has hypolipidemic effect, decreases the total cholesterol and low-density lipoproteins.

The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective effect.

It inhibits lipid peroxidation, increases superoxidase activity, increases lipid-protein ratio, decreases membrane viscosity and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine) that increases their ability to bind to ligands, maintains structural and functional organization of biomembranes, neurotransport and improves synaptic transmission.

Mexiprim increases dopamine content in the brain.

Causes compensatory activation of aerobic glycolysis and reduction of the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Indications

Anxiety disorders in neurotic and neurosis-like conditions;
vegetative-vascular dystonia;
mild cognitive disorders of various origins (with psychoorganic syndrome and asthenic disorders caused by acute and chronic cerebrovascular accidents, traumatic brain injuries, neuroinfections and intoxications, senile and atrophic processes);
memory disorders and intellectual disability in the elderly;
exposure to extreme (stress) factors;
alcohol withdrawal syndrome with a predominance of neurosis-like and vegetative-vascular disorders.

Pharmacological effect

Mexiprim is a heteroaromatic antioxidant.

It has a wide range of pharmacological activity: it increases the body’s resistance to stress, exhibits an anxiolytic effect that is not accompanied by a muscle relaxant effect; has nootropic properties, prevents and reduces learning and memory disorders that occur with aging and exposure to various pathogenic factors; has an anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol.

The drug improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of blood, and reduces platelet aggregation.

Stabilizes the membrane structures of blood cells (erythrocytes and platelets). Has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.

The mechanism of action of Mexiprim is due to its antioxidant and membrane protective effect.

It inhibits lipid peroxidation, increases superoxide oxidase activity, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport of neurotransmitters and improve synaptic transmission.

Mexiprim increases dopamine levels in the brain.

Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

1 tablet contains:

Active substance:

Ethylmethylhydroxypyridine succinate in terms of 100% substance – 0.125 g.

Excipients (tablet core):

Kaolin – 0.00247 g,

Sodium carboxymethyl starch – 0.01258 g,

Microcrystalline cellulose – 0.1135 g,

Povidone – 0.0134 g,

Talc – 0.0053 g,

Calcium stearate – 0.00275 g

Excipients (shell):

Hypromellose – 0.00495 g,

Macrogol – 0.00128 g,

Titanium dioxide – 0.00165 g,

Talc – 0.00037 g.

Contraindications

Increased individual sensitivity to Mexiprim;
acute dysfunction of the liver and kidneys;
childhood;
pregnancy;
breast-feeding.

Side Effects

Individual adverse reactions may occur: nausea and dry mouth, drowsiness, allergic reactions.

Interaction

Compatible with psychotropic drugs.

Enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa), reduces the toxic effect of ethyl alcohol

Overdose

Symptoms: sleep disturbance (insomnia, in some cases drowsiness).

Treatment: as a rule, not required – symptoms disappear on their own within 24 hours. In severe cases of insomnia, it is recommended to take nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

Obninsk HFC, Russia